CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
Pertuzumabdrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Recurrent, histologically or cytologically documented NSCLC (squamous cell, adenocarcinoma, or large cell anaplastic)
  • ✓Measurable disease with lesions ≥20 mm by conventional imaging or ≥10 mm by spiral CT
  • ✓Progression during or after ≥1 prior chemotherapy regimen containing platinum, taxane, or vinca alkaloid
  • ✓Tumor accessible to biopsy and willingness to undergo biopsy
Key exclusion· 11
  • ✕Prior treatment with any HER pathway inhibitors (Herceptin, Iressa, Tarceva, C225, CI1033, TAK165)
  • ✕Histologically documented bronchioalveolar carcinoma
  • ✕Clinical or radiographic evidence of CNS or brain metastases
  • ✕Ejection fraction <50% on ECHO

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00063154
NCT00063154Phase 2Completed
CompareCT.gov

A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer

Genentech, Inc.·interventional·Posted Jun 25, 2003·Updated Jul 7, 2015

In Brief

A Phase 2 clinical trial evaluating Pertuzumab for Non-small Cell Lung Cancer. Completed, enrolled 51 participants across 8 sites.

Detailed Summary

The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2003
Enrollment StartJul 1, 2003
Primary CompletionApr 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 23.0 years ago

Interventions

Pertuzumabdrug

Pertuzumab was supplied as a single-use liquid formulation.